King/Palatin Put Phase III Plans For Erectile Dysfunction Product On Hold
This article was originally published in The Pink Sheet Daily
Executive Summary
Risk/benefit profile for bremelanotide unacceptable for first-line use, but compound may have value as second-line therapy for PDE-5 nonresponders, FDA says.
You may also be interested in...
Deal Watch: Infinity Scores With AbbVie Deal, AbbVie Tries New Angle With Calico
Infinity gains street cred with AbbVie partnership on duvelisib, while AbbVie also branches out into aging disease by obtaining a stake in Google’s Calico; Palatin and Gedeon Richter pair up on female sexual dysfunction; and AstraZeneca finds an oncology discovery engine in Redx.
King Cuts Workforce By 20% In Wake Of Altace Decision
Size and focus of sales force will be restructured, King says.
King Cuts Workforce By 20% In Wake Of Altace Decision
Size and focus of sales force will be restructured, King says.